Oxford Gene Technology appointed John Anson as research and development director, the company said today.
Anson spent 16 years at Amersham Biosciences/GE Healthcare where he held various executive positions, including head of product development. He worked on his post-doctorate research at PHLS Centre for Applied Microbiology and Research, Porton Down, and holds a PhD in bacterial genetics from Cranfield University and a BSc in microbiology from the University of Kent.
Exiqon A/S announced today that Michael Kallelis will head the company's US operations in Boston, Mass. as president and general manager.
Before joining Exiqon, Kallelis was vice-president at Archemix and executive vice-president and general manager at Avecia Biotechnology. He co-founded Boston BioSystmes, which was acquired by Avecia in 1999.
Gordon J. Brown joined Orchid Cellmark as the new senior vice-president of global laboratory operations, effective Jan. 1, according to documents filed with the Securities and Exchange Commission last week.
Brown will receive an initial annual base salary of $215,000, and will have a bonus target each year of 30 percent of his base salary based on performance measures. His severance package entitles him to payments equal to 12 months salary plus a prorated portion of his annual bonus.
Epigenomics named Mike Wendall as senior vice-president for clinical, regulatory and quality, and James Douglas as senior vice-president of marketing and sales, the company said today.
Both Wandell and Douglas will be based in Seattle, Wash.
Wandell brings 25 years of experience to Epigenomics. He was director of business development and regulatory affairs with Genetic Systems, chief scientific officer at Home Access Health, and vice-president of clinical & regulatory affairs with LipoSonix.
Douglas spent 18 years in biotechnology companies including Gen-Probe, Sanofi Diagnostics Pasteur, Centocor, Abbott Diagnostics and Biosite.
William Slikker, Jr. has been named as the acting director of the National Center for Toxicological Research, the US Food and Drug Administration announced yesterday.
Slikker replace Dan Casciano, the NCTR Director for more than six years. Casciano is moving into the private sector to work on molecular, cellular, and general toxicology issues.
Most recently, Slikker was NCTR's deputy center director for research. He received his B.A. degree in biology from the University of California Santa Barbara and a Ph.D. in pharmacology and toxicology from the University of California Davis.
Kevin Conroy, Third Wave Technologies' new president and chief executive, has a new compensation package, according to documents filed with the Securities and Exchange Commission late last week.
Conroy will receive a base salary of $375,000 and is eligible to earn up to 50 percent of his base salary in bonuses. Third Wave also gave Conroy 250,000 incentive stock options under the 2000 Stock Plan, with an exercise price of $2.82 and a term of 10 years. Options will vest in equal installments over a four-year period, according to the filing.
He is entitled to four weeks of paid vacation each calendar year and reimbursement up to $60,000 in relocation expenses and "reasonable and necessary" out-of-pocket expenses.
If Conroy leaves Third Wave, he will receive severance pay for 18 months at his then current base salary, any accrued but unpaid base salary as of the termination date, any accrued but unpaid bonus amounts, and accelerated vesting of 50 percent of his stock options.